September 09, 2020

Chinese Biotech Sector is Blowing Hot as M&A and IPO Deals Surge Amid Covid-19 Pandemic

Toto Ku, Datasite Senior Sales Director, provides comments on the outlook for the Chinese biotech sector, including the surge in M&A and IPO deals amid the COVID-19 pandemic. The South Morning China Post article highlights findings from a recent webinar discussion on Deal Drivers in the Healthcare and Life Sciences: Mainland China.

  • Datasite for Healthcare

    Navigating the healthcare and life sciences industry has never been harder. Whether you’re looking at a licensing, listing or M&A, achieve your objective quickly and keep sensitive data secure with Datasite.

Contacts

Media Relations
Marta Carraro

Vice President, Communications

212.367.6162

[email protected]

Investor Relations
Jennifer Percy

Senior Vice President, Finance & Treasury

651.632.4009

[email protected]

You may also like:

Three Things to Know When Taking a Public Company Private

CEO Rusty Wiley writes about the surge in take-private deals and how technology can help, especially when it comes to managing outreach and pipeline.

Forbes
US PE Firm Looks at Lukoil Asset as Sanctions Bite; Tikehau-backed Mecachrome Takes Flight with Rossi Aero

Datasite's September Deal Forecaster highlights which sector is expected to see the most global M&A activity in the coming months.

Global M&A Specialist Opens Manchester Office

EMEA CRO Merlin Piscitelli and VP of Sales Jon Hughes discuss Datasite's newest office in Manchester.